Last updated: February 21, 2026
What is the Drug Identified by NDC 50111-0561?
NDC 50111-0561 corresponds to Ublituximab, a monoclonal antibody approved for treatment of relapsing forms of multiple sclerosis (MS). Ublituximab is marketed under the brand name Briumvi (U.S.) by TG Therapeutics. It received FDA approval in December 2022.
Market Overview
Therapeutic Area and Competition
Ublituximab targets CD20-positive B cells, similar to other MS drugs. Its main competitors include:
- Ocrelizumab (Ocrevus)
- Ofatumumab (Kesimpta)
- Rituximab (off-label use)
| Product |
Indication |
Approval Year |
Market Share (2022) |
Manufacturer |
| Ocrelizumab |
MS, primary progressive MS |
2017 |
45% |
Roche/Genentech |
| Ofatumumab |
MS |
2020 |
20% |
Novartis |
| Rituximab |
Off-label MS, others |
1997 |
10% |
Roche |
| Ublituximab |
MS |
2022 |
Pending |
TG Therapeutics |
Market Size and Growth
The U.S. MS drug market exceeds $7 billion annually. Monoclonal antibodies form around 70% of the segment. Ublituximab's initial penetration depends on:
- Efficacy advantages
- Pricing strategies
- Physician adoption
Pricing Context
- Ocrevus: $65,000–$70,000 annually
- Kesimpta: ~$65,000 annually
- Rituximab (off-label): ~$20,000–$30,000 annually
Ublituximab pricing was set at approximately $65,000 per year upon launch, aligning with competitors but offering potential differentiation in dosing regimen.
Price Projections and Revenue Estimates
Assumptions
- Year 1 (2023): 2,000 patients
- Year 2 (2024): 5,000 patients
- Year 3 (2025): 10,000 patients
- Price per patient: $65,000 annually
Revenue Forecasts
| Year |
Patients |
Revenue (USD millions) |
Market Penetration (%) |
| 2023 |
2,000 |
130 |
3% |
| 2024 |
5,000 |
325 |
5% |
| 2025 |
10,000 |
650 |
10% |
Growth Dynamics
- Initial slow uptake due to market dominance of existing drugs.
- Accelerating adoption as clinical data highlights improvements in efficacy or reduced side effects.
- Price adjustments could occur based on reimbursement negotiations.
Regulatory and Commercial Factors
- Reimbursement: Payers require comparative effectiveness data. Price negotiations could reduce net revenue.
- Physician Acceptance: Influenced by ease of infusion, efficacy, safety profile.
- Market Entrenchment: Established drugs hold high loyalty; switching costs impact penetration rates.
Competitive Pricing Strategies
- Penetrate through value-based pricing.
- Offer discounts for bulk contracts.
- Leverage unique dosing or administration advantage to justify premium pricing.
Risk Factors
- Competition from well-established therapies.
- Off-label use of rituximab influencing demand.
- Regulatory hurdles in expanding indications.
Key Takeaways
- Ublituximab entered a mature MS market with high established brand presence.
- Initial pricing aligns with competitors, supporting a positive revenue outlook with early patient acquisition.
- Market penetration remains limited in early years but could grow with positive clinical outcomes and clinician acceptance.
- Revenue projection for 2023–2025 ranges from $130 million to $650 million based on uptake.
- Price sensitivity and reimbursement policies significantly impact long-term profitability.
FAQs
1. How does the efficacy of ublituximab compare to competitors?
Clinical trial data indicates comparable or superior efficacy in reducing relapse rates. Long-term comparative studies are ongoing.
2. Will pricing differ in international markets?
Prices vary based on country-specific negotiations, healthcare systems, and reimbursement policies.
3. What is the potential for off-label use of ublituximab?
Existing drugs like rituximab are used off-label for MS, potentially offsetting demand for new therapies initially.
4. How does infusion frequency impact market uptake?
Ublituximab's infusion schedule may be more convenient, favoring adoption over less frequent or more complex regimens.
5. What are the main regulatory considerations?
Additional approvals for other indications or expanded patient populations could drive revenue growth; ongoing safety monitoring remains essential.
Citations
[1] FDA. (2022). Ublituximab (Briumvi) Approval Letter.
[2] IQVIA. (2022). Neurology Market Data.
[3] TG Therapeutics. (2022). Ublituximab (Briumvi) Prescribing Information.
[4] EvaluatePharma. (2022). Oncology and Immunology Drug Market Report.
[5] Centers for Medicare & Medicaid Services. (2022). Reimbursement and Pricing Data.
